Bevacizumab and Trabectedin +/- Carboplatin in Advanced Ovarian Cancer
Status:
Completed
Trial end date:
2018-03-18
Target enrollment:
Participant gender:
Summary
This study is aimed at assessing the efficacy and the safety of the combination of
bevacizumab and trabectedin with or without carboplatin in adult women with epithelial
ovarian cancer at first recurrence occurred 6-12 months after the end of the last (first or
second) platinum-containing regimen. According to the Bryant and Day design the primary
endpoints will be the proportion of progression-free patients at 6 months for the efficacy,
and the proportion of patients with severe toxicity for the safety at the same time-point.
Phase:
Phase 2
Details
Lead Sponsor:
Mario Negri Institute for Pharmacological Research